1 Supplementary Materials





6 device is filled with fibrin gel.

Α







13





5 Figure S3. Single niche controls expressed markers associated with *in vivo* bone marrow. Endothelial cells

- 16 (CD34 or CD31, red) and osteopontin, leptin, VCAM-1, ICAM-1, and SDF-1 (all green). Nuclei were counterstained
- 17 with DAPI (blue). Scale bar: 50 µm. Expression of SDF-1/CXCL-12 was muted in the single niche perivascular
- 18 control compared to the BMoaC.



Supplemental Figure 4





Figure S5. Functional characterization and quantification of HSPC isolated from BMoaC, SN controls, and
 monolayer controls. (A) Representative images of CFU colonies generated by cells collected from BMoaC devices

30 following 14 days of culture. Colonies were quantified according to their morphology. (**B**, **D**, **F**) BMoaC, (**C**, **E**, **G**)

31 SN, and monolayer controls showed different CFU potential for (**B**, **C**) erythroid and (**D**, **E**) myeloid lineages. There

- 32 were no significant differences between the endosteal and the perivascular niches of the BMoaC; both niches
- 33 supported erythroid and myeloid CFU and had a similar number of total colonies, biological replicates with n=10-11.
- 34 SN controls supported erythroid and myeloid CFU. Monolayer controls, including CD34⁺ cells cultured on BMSC,
- had a limited ability to support cells with erythroid CFU potential past day 7 or to support cells with myeloid CFU
- 36 potential. (F, G) The total number of CFU was much higher in the SN than the monolayer controls. (H) SN and
- 37 monolayer controls differed in their ability to maintain a stem/progenitor cells (CD34⁺/CD133⁺ and CD34^{+/}CD133⁻)
- 38 over time.
- 39





```
Supplemental Figure 6
```

Figure 6. O₂ tension in the endosteal and perivascular niches of the BMoaC decreased over time. (A) Maps of
O₂ tension in the endosteal (left) and perivascular (right) chambers of a BMoaC device on days 7, 10, and 14.
Measurements were collected using phosphorescence lifetime imaging microscopy (PhLIM) and the oxygen sensitive
dye Oxyphor G4. (B) Brightfield images of the tissue chambers from panel A.





56	in the BMoaC. (C) Exposure to 30 ng/mL of G-CSF did not change the number of tissue resident cells in either niche
57	of the BMoaC. In contrast, egressed cells from the perivascular niche increased significantly compared to control
58	niches and treated endosteal niches (from the same devices; **p<0.01, ***p<0.0001, 2-way ANOVA with Tukey's
59	post hoc comparison test). (D) G-CSF significantly increased the ratio of CD66b ⁺ :CD33 ⁺ cells for both adherent and
60	non-adherent cells in the monolayer control. In the BMoaC, this ratio was significantly increased only in tissue
61	resident cells from the perivascular niche (*p<0.05, 2-way ANOVA with Sidak's post hoc comparison).





Soluble Signaling/Growth = $\frac{EBC_{TX} - PBC_{TX}}{EBC_{TX} + PBC_{TX}}$

Supplemental Figure 8

68 Figure S8. Characterization of MDA-MB-231 growth kinetics and response to soluble signaling in the BMoaC. 69 (A) Cancer cell growth in the bottom chamber of fibrin-only and BMoaC devices was quantified over 9 days via a 70 change in fluorescent area. (B) Growth on either side of the bottom chamber and overall growth were compared to 71 assess the bias, if any, introduced by soluble signaling from the endosteal or perivascular niches. Positive and 72 negative values indicated biased growth towards the endosteal and perivascular sides, respectively. There was no 73 statistical difference from 0 over time. (C) A cartoon representation of the BMoaC device depicting the method used 74 to analyze the effect of soluble signaling on growth. EBC: Endosteal half of the bottom chamber, PBC: Perivascular 75 half of the bottom chamber, TX: Time X.

76

Fluorophore/host Antigen Vendor Cat # CD34 APC BioLegend 343510 Alexa Fluor 488 Novus Biologicals NB300-144AF488 Laminin CD54 Alexa Fluor 488 BioLegend 322713 CD62E APC **BD** Biosciences 551144 CXCL-12 PE R&D Systems IC350P Alexa Fluor 488 Nestin ThermoFisher 53-9843-80 CD90 FITC BioLegend 328108 CD14 Brilliant Violet 421 BioLegend 325628 Pacific Blue BioLegend 348805 Lineage ThermoFisher Mouse MS-353-S CD31 (JC/70A) Rabbit VCAM-1 Abcam ab134047 Osteopontin* Rabbit Abcam ab8448 Leptin Rabbit ThermoFisher PA1-052 Goat anti-Rabbit IgG* Alexa Fluor 488 Invitrogen A-11008 Goat anti-Mouse IgG* Alexa Fluor 555 Invitrogen A-21422 SytoxOrange N/A ThermoFisher S11368 DAPI N/A ThermoFisher D1306

78 Table S1. Immunofluorescent antibodies. Antibodies were used at 1:100 unless otherwise noted.

79

77

82 **Table S2. Flow cytometry antibodies.** Antibodies were used in a final volume of 100 μL.

80

81

*Used at 1:1000

Antigen	Fluorophore	Vendor	Cat #	Vol. per test
CD14	Alexa Fluor 700	BioLegend	325614	5 µL
CD15	APC/Cy7	BioLegend	323048	5 µL
CD33	Brilliant Violet 510	BioLegend	366610	5 µL
CD34	APC	BioLegend	343510	5 µL
CD45	FITC	BioLegend	368508	5 µL
CD133	PE	BioLegend	372804	5 µL
Lineage	Pacific Blue	BioLegend	348805	20 µL
Live/Dead	Fixable Yellow	ThermoFisher	L34959	1 μL

86 87	Movie S1. Microvascular networks in the BMoaC were perfused with 70 kDa TRITC-dextran.
88	
89	Movie S2. CD34 ⁺ -derived cells migrated through the device, into the fluidic lines, and to the adjacent chamber.
90	10-hour timelapse video of a BMoaC on Day 6 of culture. Images were acquired every twenty minutes.
91	
92	Movie S3. Confocal Z-stack of the BMoaC endosteal niche. In the region shown in Fig. 3Ci, a blood vessel
93	surrounds a colony of CD34 ⁺ (red) and Lin ⁺ (green) cells in the endosteal niche.
94	
95	Movie S4. Confocal Z-stack of the BMoaC perivascular niche. In the region shown in Fig. 3Cii, CD34 ⁺ (red) and
96	Lin ⁺ (green) are seen coming in and out of focus. A blood vessel is located on the left side of the images.
97	